Quinolines (including Hydrogenated) Patents (Class 514/311)
  • Patent number: 11007157
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: May 18, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Patent number: 10973788
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: April 13, 2021
    Assignee: Io Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • Patent number: 10912743
    Abstract: Provided herein are compositions useful for treating inflammation in a subject and methods of decreasing inflammation in the skin, mucosa, and/or eye of a subject comprising applying a pharmaceutical composition that includes an NO-releasing compound to the skin, mucosa, and/or eye of the subject in an amount sufficient to decrease inflammation.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 9, 2021
    Assignee: Novan, Inc.
    Inventors: Nathan Stasko, Ryan Doxey, Kimberly McHale, Stanley J. Hollenbach
  • Patent number: 10889548
    Abstract: The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2?-halo-1-1?-biphenyl-4-yl)-quinoline carboxylic acids, which are useful as DHODH inhibitors.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: January 12, 2021
    Assignee: Clear Creek Bio, Inc.
    Inventors: Vikram S. Kumar, David P. Hesson, Ping Huang, Mo Jia, Xianjun You
  • Patent number: 10864198
    Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.
    Type: Grant
    Filed: July 30, 2017
    Date of Patent: December 15, 2020
    Assignee: Kowa Company, Ltd.
    Inventors: Ryu Oshima, Gary Gordon
  • Patent number: 10835524
    Abstract: The invention pertains to compositions comprising inhibitors of PI3K, AKT and/or mTOR, one or more 4-quinolinemethanols and a pharmaceutically acceptable excipient. These compositions can contain subtherapeutic amounts of each active ingredient (PI3K, AKT, mTOR, one or more 4-quinolinemethanols and various combinations thereof). The invention also provides a method of treating various forms of cancer, such as breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, brain cancer, lung cancer, non-small cell lung carcinoma, colorectal cancer, melanoma and/or pancreatic cancer.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: November 17, 2020
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Maria Zajac-Kaye, Rony A. Francois
  • Patent number: 10786494
    Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: September 29, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Daniel Dairaghi, Dean R. Dragoli, Jaroslaw Kalisiak, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Rebecca M. Lui, Venkat Reddy Mali, Viengkham Malathong, Jay P. Powers, Hiroko Tanaka, Joanne Tan, Matthew J. Walters, Ju Yang, Penglie Zhang
  • Patent number: 10758529
    Abstract: Methods for inhibiting the activity of Clostridium difficile in a subject comprises administering to the subject in need thereof, a therapeutically effective amount of azaquinone or a pharmaceutical composition consisting of clofazimine or a clofazimine analogue, azaquinone, and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions comprising a therapeutically effective amount of azaquinone or consisting of clofazimine or a clofazimine analogue, azaquinone, and at least one pharmaceutically acceptable excipient are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: September 1, 2020
    Assignee: KamTek, Inc.
    Inventors: Venkata M. Reddy, Wolf Prensky, Sharanjit VedBrat
  • Patent number: 10759762
    Abstract: There are described novel compounds of formula I: which R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are each as herein defined.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: September 1, 2020
    Assignee: HIGH FORCE RESEARCH LIMITED
    Inventors: Andrew Whiting, Todd Marder
  • Patent number: 10752607
    Abstract: The invention provides new polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 25, 2020
    Assignee: KALVISTA PHARMACEUTICALS LIMITED
    Inventors: Haydn Beaton, Jonathan Yates Boxhall, David Malcolm Crowe
  • Patent number: 10738005
    Abstract: Described herein are compositions and compounds having one or more aziridinyl groups, and methods of making the same. The compounds can also have one or more nitrogen atoms that each can be positively charged. The composition and compounds can inactivate one or more nucleic acid molecules (e.g. a DNA and/or a RNA from a pathogen) in a sample. The sample can comprise a blood or blood product (e.g., donated blood). The compositions and compounds can inactivate any nucleic acid present in a blood or blood product, thereby making the blood or blood product safe for use (e.g., in a transfusion).
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: August 11, 2020
    Assignee: ZATA Pharmaceuticals, Inc.
    Inventor: David R. Tabatadze
  • Patent number: 10729683
    Abstract: Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: August 4, 2020
    Assignee: TOCHIGI INSTITUTE OF CLINICAL PATHOLOGY
    Inventor: Masao Sugamata
  • Patent number: 10654808
    Abstract: The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: May 19, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Chaofeng Long, Zhengxia Chen, Xiaoxin Chen, Yang Zhang, Zhuowei Liu, Peng Li, Shuhui Chen, Guibai Liang, Cheng Xie, Zhengwei Li, Zhifei Fu, Guoping Hu, Jian Li
  • Patent number: 10626089
    Abstract: Crystals of [8-chloro-3-(4-chlorobenzyl)-4-difluoromethoxy-2-ethylquinolin-5-yloxy]acetic acid L-lysine salt, i.e., a crystal A which has peaks at diffraction angles 2?=6.0°, 10.0°, 10.7°, 12.1°, 18.4°, 19.2° and 20.1° in powder X-ray diffraction spectra and a crystal B which has peaks at diffraction angles 2?=6.0°, 11.7°, 12.4°, 15.2°, 16.4°, 20.3° and 22.6° in powder X-ray diffraction spectra. These crystals are chemically stable and have excellent thermal stability and physical properties, and are therefore suitable as medicinal substances.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: April 21, 2020
    Assignee: GBOO1, Inc.
    Inventors: Donald John Daley, John Gary Montana, George Hynd, Mitsuru Teramoto, Takahiro Ito
  • Patent number: 10588874
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 17, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Patent number: 10570378
    Abstract: The present disclosure provides compositions and methods for acetylating histones at targeted chromosomal locations in a cell. In particular, the disclosure provides a fusion protein comprising a DNA binding domain and at least one histone acetyltransferase (HAT) domain, such that the DNA binding domain targets the fusion protein to a targeted chromosomal location and the HAT domain acetylates histones at the targeted location.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: February 25, 2020
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Qingzhou Ji, Carol Kreader
  • Patent number: 10556879
    Abstract: Disclosed are a retinoid compound, a preparation method therefor, intermediates thereof and an application thereof. The retinoid compound I of the present invention has a good tumor growth inhibition rate.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: February 11, 2020
    Assignees: SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADMENY OF SCIENCES, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Xin Cao, Biao Yu, Ning Wang, Junwei Chen
  • Patent number: 10543181
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 28, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Patent number: 10487058
    Abstract: A cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and applications thereof, wherein the structural formula of the compound is as follows: An application of the compound or its pharmaceutically acceptable salts, hydrates, solvates, or prodrugs in preparing a drug for treating and/or preventing and/or delaying and/or providing adjuvant therapy for asthma and/or allergic rhinitis and asthma syndromes is provided. A drug composition includes the cyclopropyl unsaturated quinoline compound or the pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof. The compound series has favorable foreground in preparing drugs for treating and/or preventing and/or delaying and/or providing adjuvant therapy for asthma and/or allergic rhinitis and asthma syndromes.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: November 26, 2019
    Assignee: Guangdong Moltech Pharma Co. Ltd.
    Inventor: Yingjie Lai
  • Patent number: 10472326
    Abstract: The present invention relates to compounds according to general formula (I); to pharmaceutical compositions comprising one or more of the compound(s); and to the use of the compound(s) as anti-infectives.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: November 12, 2019
    Assignee: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH
    Inventors: Cenbin Lu, Christine K. Maurer, Benjamin Kirsch, Anke Steinbach, Rolf W. Hartmann, Mathias Müsken, Susanne Häussler
  • Patent number: 10457658
    Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: October 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Lars Dobelmann-Mara, Stefan Riedmueller, Martin Schraub
  • Patent number: 10421753
    Abstract: The present invention includes novel RAD51 inhibitors. The compounds of the invention may be useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: September 24, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jiewen Zhu, Wen-Hwa Lee, Hongyuan Chen, Xuning Guo, Xiao-Long Qiu
  • Patent number: 10383835
    Abstract: The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: August 20, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Alonso G. P. Guedes, Bruce D. Hammock, Christophe Morisseau
  • Patent number: 10369146
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: August 6, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings
  • Patent number: 10366131
    Abstract: The concepts relate to task completion and specifically to aiding a user to complete an unfinished task at a subsequent time and/or on another device. One example can identify that a user is working on a task on a computing device associated with the user. In an instance when the user stops using the computing device without completing the task, the example can predict a likelihood that the user will subsequently resume the task on a second computing device associated with the user. In an instance where the likelihood exceeds a threshold, the example can attempt to aid the user in completing the task on the second computing device.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: July 30, 2019
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Ryen W. White, Zijian Zheng, An Yan, Xiao Huang, Yu Wang
  • Patent number: 10301308
    Abstract: The present invention provides a novel compound of the formula: methods of making this compound, methods of using this compound for tau imaging, and preparations of tau imaging formulations.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: May 28, 2019
    Assignee: Eli Lilly and Company
    Inventors: Giorgio Attardo, Carey Lynn Horchler, Shyamali Ghosh, Hui Xiong
  • Patent number: 10195167
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: February 5, 2019
    Assignee: Glucox Biotech AB
    Inventors: Per Wikström, Erik Walum, Mona Wilcke
  • Patent number: 10149846
    Abstract: Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: December 11, 2018
    Assignee: TOCHIGI INSTITUTE OF CLINICAL PATHOLOGY
    Inventor: Masao Sugamata
  • Patent number: 10117865
    Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: November 6, 2018
    Assignee: ChemoCentryx, Inc.
    Inventors: Daniel Dairaghi, Dean R. Dragoli, Jaroslaw Kalisiak, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Rebecca M. Lui, Venkat Reddy Mali, Viengkham Malathong, Jay P. Powers, Hiroko Tanaka, Joanne Tan, Matthew J. Walters, Ju Yang, Penglie Zhang
  • Patent number: 10100029
    Abstract: The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: October 16, 2018
    Assignee: BioVentures, LLC
    Inventors: Narsimha Reddy Penthala, Peter Crooks, Vijayakumar Sonar
  • Patent number: 10058546
    Abstract: A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: August 28, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Rossitza Gueorguieva Alargova, Craig Antony Dunbar, Irina Nikolaevna Kadiyala
  • Patent number: 10039731
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: August 7, 2018
    Assignee: Io Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • Patent number: 9968584
    Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: May 15, 2018
    Assignee: Cardioxyl Pharmaceuticals, Inc.
    Inventors: Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost, John P. Toscano
  • Patent number: 9938252
    Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described; which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: April 10, 2018
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Leticia Toledo-Sherman, Michael Prime, William Mitchell, Naomi Went
  • Patent number: 9931335
    Abstract: Compositions and methods are provided for inhibiting or treating the early and established stages of inflammatory diseases by administration of an effective dose of the desethylhydroxychloroquine (DHCQ). A benefit of the methods is the ability to deliver a dose of agent that is effective in treating inflammation while sparing the individual from retinal toxicity.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: April 3, 2018
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: William H. Robinson, Jeremy Sokolove, Qian Wang
  • Patent number: 9796736
    Abstract: Provided are a heterocyclic compound which emits blue light and is represented by General Formula (G1) below, and a light-emitting element, a light-emitting device, an electronic device and a lighting device which are formed using the heterocyclic compound represented by General Formula (G1) below. The use of the heterocyclic compound represented by General Formula (G1) makes it possible to provide a light-emitting element which has high emission efficiency, and also a light-emitting device, an electronic device and a lighting device which have reduced power consumption.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: October 24, 2017
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hiroki Suzuki, Tsunenori Suzuki, Satoshi Seo
  • Patent number: 9775836
    Abstract: Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: October 3, 2017
    Assignee: TOCHIGI INSTITUTE OF CLINICAL PATHOLOGY
    Inventor: Masao Sugamata
  • Patent number: 9751885
    Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: September 5, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Naoki Tomita, Daisuke Tomita, Yusuke Tominari, Shinichi Imamura, Shinji Morimoto, Takuto Kojima, Masashi Toyofuku, Yasushi Hattori, Tomohiro Kaku, Mitsuhiro Ito
  • Patent number: 9737523
    Abstract: Presented herein are methods for treatment of diseases or conditions related to fibrosis. Compounds, or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof provide for the treatment of diseases or conditions related to fibrosis.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: August 22, 2017
    Assignee: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Aziz Ghahary, Yunyuan Li, Ruhangiz T. Kilani, Ryan Hartwell
  • Patent number: 9717702
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: August 1, 2017
    Assignee: IO Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • Patent number: 9717746
    Abstract: Synthetic ether alkyl-lysophospholipids (APLs) provide an effective treatment for subjects suffering from cholinergic seizures. Among other uses, APLs may be used to treat the effects of epileptic seizures in particular cholinergic seizures caused by exposure to insecticides or chemical warfare nerve agent exposure. Edelfosine, an APL, has been show to be particularly effective in these areas.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: August 1, 2017
    Inventor: Peter Andrew Ferchmin
  • Patent number: 9714238
    Abstract: This invention provides well defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds for treating glaucoma or ocular hypertension.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 25, 2017
    Assignee: ALLERGAN, INC.
    Inventor: David W. Old
  • Patent number: 9701627
    Abstract: Compounds, and methods of using the same, are provided as therapies for the treatment leucine-rich repeat kinase-2 (LRRK2)-related disorders including, but not limited to, neurodegenerative and neuroinflammatory disorders, such as Parkinson's Disease.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: July 11, 2017
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Wanli Smith, Fengtian Xue, Alexander D MacKerell, Jr.
  • Patent number: 9655872
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: May 23, 2017
    Assignee: IO Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • Patent number: 9630918
    Abstract: Cysteine, N-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions comprising the cysteine, N-acetylcysteine, and penicillamine related compounds, and methods of using cysteine, N-acetylcysteine, and penicillamine related compounds and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including paracetamol overdose, non-alcoholic steatohepatitis, Wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, Parkinson's disease, and Huntington's disease.
    Type: Grant
    Filed: September 19, 2015
    Date of Patent: April 25, 2017
    Inventor: Mark Quang Nguyen
  • Patent number: 9629835
    Abstract: A method for treating tau-associated disease by administering a pharmaceutical composition comprising a quinoline derivative to a subject in need is disclosed. Particularly, a method for treating Alzheimer's disease by administering a pharmaceutical composition comprising a quinoline derivative to a subject in need is disclosed. The two disclosed quinoline derivatives have the inhibition effect for GSK-3? kinase activity, so as the two disclosed quinoline derivatives have the ability for inhibiting tau hyperphosphorylation or reducing tau aggregation.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: April 25, 2017
    Assignee: National Taiwan Normal University
    Inventors: Guey-Jen Lee-Chen, Hsiu-Mei Hsieh, Guan-Chiun Lee, Ying-Chieh Sun
  • Patent number: 9593136
    Abstract: In particular, the compound is effective to inhibit Dxr in Mycobacterium tuberculosis (Mtb). The present invention relates to compounds having general formula (I) or (II) where X is an acidic group, such as carboxylate, phosphonate, sulfate, and tetrazole; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and n is 0, 1, 2, 3, or 4, preferably 2, 3, or 4. The compounds inhibits 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr), particularly Dxr in Mycobacterium tuberculosis (Mtb).
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 14, 2017
    Assignees: The George Washington University, George Mason University, St. Jude Children's Research Hospital, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Helena I. Boshoff, Cynthia S. Dowd, Emily R. Jackson, Kylene Kehn-Hall, Richard E. Lee, Robin Lee, Geraldine San Jose
  • Patent number: 9539303
    Abstract: The present invention provides compositions and methods for the treatment of /??s-expressing tumors using at least one DAC inhibitor (e.g., romidepsin).
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: January 10, 2017
    Assignee: Celgene Corporation
    Inventors: William McCulloch, Mitchell Keegan
  • Patent number: 9540373
    Abstract: This invention relates to a compound of formula I wherein A and Cy have one of the meanings as indicated in the specification and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: January 10, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Viktor Vintonyak, Matthias Grauert, Marc Grundl, Alexander Pautsch
  • Patent number: RE47636
    Abstract: This invention relates to a compound of formula I wherein A and Cy have one of the meanings as indicated in the specification and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: October 8, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Viktor Vintonyak, Matthias Grauert, Marc Grundl, Alexander Pautsch